Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amdizalisib in Relapsed/Refractory MZL and FL
NCT04849351Phase 2Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Apr 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amdizatinib in marginal zone lymphoma (MZL), follicular lymphoma (FL), sponsored by Hutchison MediPharma (HMP). Started Apr 2021; status: completed.
02
Drugs
amdizatinib
03
Conditions
marginal zone lymphoma (MZL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04849351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849351.